Truvestments Capital LLC Acquires Shares of 544 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Truvestments Capital LLC acquired a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 544 shares of the company’s stock, valued at approximately $63,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Renaissance Technologies LLC raised its holdings in shares of Neurocrine Biosciences by 9.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company’s stock worth $339,790,000 after buying an additional 216,500 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of Neurocrine Biosciences by 23.0% during the 2nd quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company’s stock worth $166,959,000 after buying an additional 228,444 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Neurocrine Biosciences by 1.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 934,404 shares of the company’s stock worth $128,639,000 after buying an additional 13,069 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in shares of Neurocrine Biosciences by 4.7% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 819,968 shares of the company’s stock worth $94,478,000 after buying an additional 37,098 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in shares of Neurocrine Biosciences by 40.3% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 710,600 shares of the company’s stock worth $97,828,000 after buying an additional 203,934 shares in the last quarter. 92.59% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on NBIX. Oppenheimer boosted their price target on Neurocrine Biosciences from $216.00 to $219.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Jefferies Financial Group upped their target price on Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a “buy” rating in a report on Monday, August 19th. StockNews.com cut Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. BMO Capital Markets lowered their target price on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a report on Thursday, October 17th. Finally, Barclays lowered their target price on Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating for the company in a report on Monday, September 9th. Five investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $163.91.

Neurocrine Biosciences Price Performance

Shares of Neurocrine Biosciences stock opened at $126.59 on Thursday. The stock’s 50-day moving average is $118.97 and its 200 day moving average is $131.71. The firm has a market cap of $12.82 billion, a price-to-earnings ratio of 33.94 and a beta of 0.35. Neurocrine Biosciences, Inc. has a one year low of $110.81 and a one year high of $157.98.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.